OGOsama Gheith

Osama Gheith

*This is an algorithmically generated author record based on publicly available information.

Osama Gheith has a total of 344 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of hypertension and hypertensive chronic kidney disease in Arab Countries

    by Osama Ghieth, Nashwa Othman, Suzann Rida, AymanMaher Nagib, Mohamed Saad, AmroM Gheith, Ahmad Abass, Torki Alotaibi

    Te (GFR) decline rate, and the underlying kidney disease, including diabetes. The prevalence of hypertension, public awareness, and risk factors are poorly understood in the Arab world. We aimed from this review to highlight the prevalence of hypertension and hypertensive chronic kidney disease in Arab countries. Materials and Methods All publications concerning hypertension and CKD among Arabs during the last 30 years were collected and reviewed. Conclusion Hypertension was prevalent in Jordon, Lybia, and Tunis; however, diabetic nephropathy was the leading cause of end-stage kidney disease (ESKD), possibly due to well-controlled hypertension or underestimated prevalence. In Saudi Arabia and Yemen, hypertension was less prevalent than that reported in Egypt, Algeria, and Sudan, and it represented the leading cause of ESKD in such countries. To overcome the variations in different studies involving Arab countries, we recommended further multicenter organized studies considering the new guidelines of hypertension classes and phenotypes....

  • Effect of Repeated Structured Diabetes Education on Lifestyle Knowledge and Self-Care Diabetes Management in Kidney Transplant Patients With Posttransplant Diabetes

    by Nashwa Othman, Torki Al-Otaibi, Medhat A. Halim, Tarek Said, Nabil Elserwy, Fatma Mahmoud, Heba Abduo, Mohamed Jahromi, Narayanan Nampoory, Osama Ashry Gheith

    Objectives: Diabetes knowledge among kidney transplant recipients with posttransplant diabetes has not been clearly assessed. We evaluated whether diabetes education in kidney transplant recipients with posttransplant diabetes affected self-care, metabolic control variables, and reversibility of early diabetic microangiopathies. Materials and Methods: In this prospective randomized controlled study, we enrolled 210 renal transplant recipients with posttransplant diabetes. Group 1 patients (n = 140) received structured diabetes education, and group 2 patients (n = 70) received conventional education. Patient data were collected through patient identification and metabolic control parameter forms and a diabetes self- care scale questionnaire (scores between 0 and 7). Results: Diet knowledge improved and waist circumference was reduced with mild to moderate exercise in group 1 (P <.001), despite no differences between the 2 groups in mean body weight or body mass index. Patients in group 1 (structured diabetes education with repeated reinforcement) showed significant improvement in healthy lifestyle parameter scores versus group 2 (P <.05) and versus values before education (P <.05). At end of study, these achievements were translated into proper blood sugar monitoring, management of both hypoand hyperglycemia, improvements in logbook use and healthy sharp disposal, Ramadan fasting, sick day management, and knowledge on the importance of HbA1c (P <.05), which translated to decrease of HbA1c in group 1 by 1.35%. In group 1, proteinuria decreased significantly compared with before education and compared with group 2 values (P =.016). Diabetic retinopathy and neuropathy remained comparable between groups (P >.05). Conclusions: Structured diabetes education improved lifestyle knowledge, self- care diabetes management, and metabolic control variables among kidney transplant recipients with posttransplant diabetes. Structured diabetes education also resulted in partial reversibility of the present early diabetic nephropathy. We recommended such education to be delivered to all kidney transplant recipients with diabetes.


  • Impact of Pretransplant Dialysis Modality on Posttransplant Outcomes: A Single-Center Experience

    by Torki Al-Otaibi, Ayman M. Nagib, Ahmed Deraz, Islam Elasawy, Suzann Rida, Mahmoud Khalid, Medhat A. Halim, Mohamed Dahab, Prasad Nair, Omar Almanea, et al.

    Objectives: It remains unclear whether posttransplant outcomes differ according to the pretransplant dialysis modality (peritoneal dialysis vs hemodialysis). Our aim was to assess posttransplant outcomes in patients with different predialysis modalities. Materials and Methods: Two thousand two hundred fifty- eight kidney recipients following up in Hamed Alessa Organ transplant center in Kuwait were included and divided into two groups according to pre-transplant dialysis modality: Group 1: those who received hemodialysis (HD) and group 2: those with peritoneal dialysis (PD). Demographics, pretransplant and posttransplant comorbidities, and patient and graft outcomes were studied. Results: There were 1956 patients on hemodialysis, and 302 patients were on peritoneal dialysis. Most were male patients (1456 vs 802 female patients), with comparable mean age ( P =.34). Chronic glomerulonephritis and diabetic nephropathy represented the most common original kidney disease before transplant (27.6% and 21.4%, respectively), with higher prevalence of glomerulonephritis in group 1 and diabetic nephropathy in group 2 (P =.001). The 2 groups were comparable with regard to immunosuppression (induction and maintenance) (P >.05). Posttransplant diabetes and hypertension were significantly higher in the hemodialysis group (P =.004 and P = 003, respectively). There was no significant difference between the 2 groups with regard to the graft outcome (P =.86). However, patient survival was significantly higher in the hemodialysis group (81.2% vs 64.4%). Conclusions: Compared with peritoneal dialysis, pretransplant hemodialysis is associated with better posttransplant patient survival despite no difference in the graft outcome. Diabetes-related complications could be attributed to such outcomes.


  • Acute Kidney Injury Among COVID-19-Positive Patients Is Associated With Higher Mortality: A Single-Center Experience

    by Torki Al Otaibi, Ayman Nagib, Prasad Nair, Medhat A. Halim, Mahmoud Khaled, Mohamed A. Hammad, Tarek S. Mahmoud, Islam Sobhy, Zakaria Zakaria, Ahmed Atta, et al.

    Objectives: Renal complications of COVID-19 are not yet well studied. We aimed to evaluate acute kidney injury prevalence among hospitalized patients with COVID-19 infection and explore its effect on patient outcomes. Materials and Methods: We retrospectively evaluated 586 hospitalized patients with COVID-19. Of these patients, 267 (45.5%) developed acute kidney injury, as classified according to the Kidney Disease Improving Global Outcomes guidelines. We compared this group with 319 patients (54.5%) without acute kidney injury. Results: Most patients in both study groups were men; mean age was 60.8 +/- 14 versus 51.7 +/- 16 years. Comorbid conditions that were substantially predominant among patients with acute kidney injury were diabetes mellitus (64% vs 42.9%), hypertension (72.6% vs 43.5%), and ischemic heart disease (25% vs 14.7%). Fever, cough, shortness of breath, and dehydration were the main presentations among patients with acute kidney injury, and patients in this group had greater prevalence of radiological findings concordant with COVID-19 (86.8% vs 59.8%). Sepsis, volume depletion, shock, arrhythmias, and acute respiratory distress syndrome were higher in patients with acute kidney injury. Anticoagulation (85% vs 59.2%), vasopressors, plasma infusions, antimicrobials, and steroids were more frequently used in patients with acute kidney injury. More patients with acute kidney injury had acute respiratory failure requiring mechanical ventilation (62.3% vs 32.9%), with higher overall mortality rate (63.2% vs 31.1%). Conclusions: We found more frequent prevalence of acute kidney injury associated with severe COVID-19 than shown in reports from Chinese, European, and North American cohorts. Patients with COVID-19 who developed acute kidney injury had risk factors such as hypertension and diabetes, greater need for mechanical ventilation, were males, and were older age. Mortality was high in this population, especially among older patients and those who developed Kidney Disease Improving Global Outcomes stage 3 disease.

  • Inhibition of Proprotein Convertase Subtilisin/Kexin-9 After Kidney Transplant: Single-Center Experience Among Patients With High Cardiovascular Risk

    by Torki Alotaibi, Ayman Maher Nagib, Ahmed Denewar, Hasaneen Aboateya, Medhat A. Halim, Tarek Mahmoud, Mohamad Abdelmonem, Zakaria El-Sayed, Mohamed Mostafa, Mohamed Emam, et al.

    Objectives: The benefits of reduction in low-density lipoprotein cholesterol by evolocumab by nearly 60% has not been evaluated among kidney transplant recipients to our knowledge. We assessed the efficacy and safety of evolocumab, a proprotein convertase subtilisin/kexin-9 inhibitor, in reducing lipids and cardiovascular events among kidney transplant recipients in a randomized controlled study. Materials and Methods: Between June 2017 and June 2019, we enrolled 197 kidney transplant recipients with high cardiovascular risk score (>20). Patients who received evolocumab (140 mg/2 weeks) comprised group 1 (n = 98), and patients maintained on statin therapy comprised group 2 (n = 99). We followed patients clinically and with necessary laboratory investigations over 24 months. Results: The 2 groups had comparable demographic characteristics (P > .05). Before enrollment in the study, smokers were significantly more prevalent in group 1, whereas posttransplant diabetes mellitus was more prevalent in group 2 (P = .033). Moreover, baseline serum creatinine was higher in group 1, whereas immunosuppression was equivalent in both groups (P > .05). We found no significant differences between the 2 groups concerning cardiovascular events, and both graft and patient outcomes were comparable (P > .05). The higher baseline cholesterol in group 1 (5.5 vs 4.7 mmol/L; P < .001) decreased significantly after 3 months and thereafter (P = .031) compared with levels in group 2 and baseline values (P < .001). We reported 2 cases of acute myocardial infarction and 1 atrial fibrillation in group 2. Conclusions: Proprotein convertase subtilisin/kexin-9 inhibitors, as an added therapy to statins, are safe and effective in treating hypercholesterolemia after kidney transplant. Evolocumab can minimize cardiovascular events after kidney transplant in patients with high events at baseline. Longer-term trials with larger number of patients are needed to confirm its beneficial effects on cardiovascular complications and patient and graft survival.


  • Full Correction of Posttransplant Anemia Is Associated With Stabilized Cardiac Dimensions Among Kidney Transplant Recipients: A Prospective Randomized Controlled Trial

    by Torki Al-Otaibi, Ayman M. Nagib, Medhat A. Halim, Hasaneen Abo-Atya, Tarek Mahmoud, Prasad Nair, Hany Adel, Ahmed Mosaad, Ahmed Fathy, Mohamed Abdul-Hameed, et al.

    Objectives: Posttransplant anemia might be associated with cardiovascular morbidity and increased mortality. To our knowledge, the debate on anemia correction has neither been revisited nor decided definitively. We aimed to assess the effects of full correction of posttransplant anemia on the cardiovascular system and quality of life among renal transplant recipients with stable graft function who were using erythropoietin-stimulating agents. Materials and Methods: We enrolled 247 kidney recipients with stable graft function to be assessed for anemia. Eligible patients were randomized to achieve targeted hemoglobin of 11 to 12 g/dL (group 1, n = 183) or of 13 to 15 g/dL (group 2, n = 64) with the use of erythropoietin-stimulating agents. Patients underwent monthly clinical and laboratory evaluations of kidney graft function. Quality of life and echocardiography were assessed at study start and at 12 months. Results: The 2 groups were comparable regarding pretransplant characteristics. In group 2, we observed comparable posttransplant complications (P > .05) but better graft function at 6 months and better cardiac indexes at 1 year of the study (P < .05). At 12 months, quality of life had improved after full correction of posttransplant anemia in the renal transplant recipients who received erythropoietin-stimulating agents. Conclusions: Full correction of posttransplant anemia in renal transplant recipients was associated with improved quality of life and cardiac indexes without an effect on cardiovascular comorbidity.


  • Kidney Transplant Recipient With Cerebral Paradoxical Embolism Following Recurrent Idiopathic Deep Vein Thrombosis and Pulmonary Embolism: Case Report and Review of the Literature

    by Osama Gheith, Hassanen Abo Atya, Ayman Maher Nagib, Ahmed Sami, Prasad Nair, Medhat Alawady, Khaja M. Sharfuddin, Ahmed Fathy, Wesam Mattar, Ahmed Abass, et al.

    Paradoxical embolism occurs when a thrombus crosses an intracardiac defect into the systemic circulation. Here, we present the case of a 35-year-old male kidney transplant recipient with a cerebral paradoxical embolism associated with a spontaneous venous thromboembolism. This patient had recurrent deep venous thrombosis and showering emboli to the lung and paradoxically to the brain through patent foramen ovale, and we treated him successfully. The role of bubble echocardiography was essential in diagnosis to avoid contrast-induced nephropathy. This is the first successfully managed case of a kidney transplant recipient with recurrent idiopathic deep vein thrombosis, pulmonary embolism, and cerebral paradoxical embolism. Bubble echocardiography was an excellent alternative to contrast angiography to avoid nephrotoxicity. Vitamin K antagonists are superior to direct oral anticoagulants, especially among nonadherent/noncompliant patients.


  • Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients

    by Tarek Mahmoud, Jude Yagan, Amal Hasan, Osama A Gheith, Mohamed Mostafa, Suzann Rida, Nabil El‐Serwi, Mohamad Shaker, Mahmoud Khalid

    Introduction: Cardiovascular and renal complications define the outcomes of diabetic kidney transplant recipients (KTRs). The new diabetes medications have changed the management of diabetes. However, transplant physicians are still reluctant to use sodium–glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) post kidney transplantation due to fear of drug related complications and lack of established guidelines.Patients and methods: We collected 1‐year follow‐up data from records of 98 diabetic KTRs on SGLT2I, 41 on GLP‐ 1RA and 70 on standard‐of‐care medicines. Patients were more than 3 months post‐transplant with a minimum estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2. Demographic data were similar except for a slightly lower HbA1c in the control group and higher albuminuria in SGLT2i group.Results: HbA1c dropped significantly by .4% in both SGLT2i and GLP‐1RA compared to .05% in the control group. A significant decrease in BMI by .32 in SGLT2i and .34 in GLP‐1RA was observed compared to an increase by .015 in control group. A tendency for better eGFR in study groups was observed but was non‐significant except for the SGLT2i group with an eGFR above 90 (p = .0135). The usual dip in eGFR was observed in the SGLT2i group at 1–3 months. Albuminuria was significantly reduced in both study groups. Adverse events were minimal with comparable safety in all groups.Conclusion: The use of SGLT2i and GLP‐1RA appears to be effective and safe in diabetic KTRs with good outcomes. Randomized control trials are required to confirm these findings and establish guidelines.


  • Open Access

    #3945 ACUTE KIDNEY INJURY (AKI) AMONG COVID-19 POSITIVE PATIENTS INCREASES THE RISK OF MORTALITY: A SINGLE CENTER EXPERIENCE

    by Torki Alotaibi, Ayman Maher Nagib, Nabil Alserwy, Ahmad Abbas, Islam Sobhy, Prasad Nair, Mahmoud Khalid, Zohair Fayad, Ahmed Atta, Mohamed Mostafa, et al.

    Background and Aims: Renal complications of COVID-19 are not yet well studied. We aimed to evaluate the prevalence of acute kidney injury (AKI) among positive COVID-19 hospitalize cases and explore its impact on patient outcomes. Method: 586 hospitalized patients with COVID-19 were retrospectively evaluated. of them, 267 (45.5%) developed AKI- classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines- compared with 319 (54.5%) patients without AKI. Results: Most cases were males (72.7% vs. 69.7%), and their ages ranged (60.8± 14 vs. 51.7± 16 years). Comorbid conditions significantly predominant among the AKI group were diabetes mellitus (64 vs. 42.9%), hypertension (72.6% vs. 43.5%), and ischemic heart disease (25% vs. 14.7%). Fever, cough, shortness of breath, and dehydration were the main presentations among the AKI group, and they had significant radiological findings concordant with COVID-19 (86.8% vs. 59.8%). Sepsis, volume depletion, shock, arrhythmias, and ARDS were significantly higher in the AKI group. Anticoagulation (85% vs. 59.2%), vasopressors, plasma infusions, antimicrobials, and steroids were more frequently used in the AKI group. Acute respiratory failure requiring mechanical ventilation and the overall mortality rate were significantly higher in the AKI group (62.3% vs. 32.9% and 63.2%. vs. 31.1%, respectively). Conclusion: AKI associated with severe COVID-19 was more frequent than reports from Chinese, European, and North American cohorts. AKI risk factors included COVID-19 comorbidities like hypertension, diabetes, mechanical ventilation, male gender, and older age. Mortality was high in this population, especially elderly patients, and in those who develop KDIGO stage 3 AKI.

  • Contrast-induced Nephropathy in Kidney Transplant Recipients: A Single-center Experience

    by Osama A. Gheith, Ayman M. Nagib, Medhat A. Halim, Tarek Mahmoud, Prasad Nair, Hasaneen Abo-Atya, Mohamed Shaker, Mohamed Mostafa, Hosam Attia, Torki Al-Otaibi

    Introduction. Data regarding contrast-induced nephropathy (CIN) in kidney transplant (KT) recipients are scarce despite the distinct risk factors such as the use of immunosuppressive agents, sympathetic denervation, glomerular hyperfiltration, and high prevalence of the cardiovascular disease. This study aimed to determine the prevalence of CIN in KT recipients who received low-osmolality iodine-based contrast material (CM) for radiological assessment. Methods. Between 2010 and 2020, 79 of the 3180 KT recipients followed at Hamed Al-Essa organ transplant center received low-osmolality iodine-based contrast for radiological assessment for various indications. Preventive measures including holding metformin, intravenous hydration, sodium bicarbonate and N-acetylcysteine were given before contrast administration. CIN was defined as an increase in serum creatinine of 25% from the baseline within 72 hours.Results. The enrolled patients were divided into two groups: those who developed CIN (n = 7) and those with no increase in serum creatinine level (n = 72). The mean age of the patients was 52.1 +/- 12.3 years; 44 of them were males, and the cause of end-stage kidney disease was mostly diabetic nephropathy. The pre-transplant demographics were comparable between the two groups. Forty-seven cases received contrast for coronary angiography, and 32 received it for a CT scan. The graft function deteriorated in group 1, but no significant difference was found between the two groups at the end of the study.Conclusion. CIN is not uncommon in KT recipients receiving CM, especially with ischemic heart disease. Risk stratification, optimizing hemodynamics, and avoiding potential nephrotoxins are essential before performing CM-enhanced studies in KT recipients.